Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL762476 | 0.96 | ESR1 (0.36) | CYP1A2SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL761290 | 0.96 | IKBKB (0.35) | CYP1A2SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL762131 | 0.96 | IKBKB (0.36) | CYP1A2SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL760880 | 0.95 | IKBKB (0.35) | CYP1A2SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL760858 | 0.94 | ESR1 (0.35) | CYP1A2SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL761322 | 0.93 | IKBKB (0.32) | CYP1A2SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL14424845 | 0.92 | ALDH1A3 (0.33) | CYP1A2SMN1; SMN2ALDH1A1HSD17B10KDM4E | |
| SCHEMBL14516043 | 0.90 | ACHE (0.33) | CYP1A2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL760861 | 0.90 | ACHE (0.33) | CYP1A2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14516040 | 0.90 | ACHE (0.33) | CYP1A2ALDH1A1KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8647753-B2 | Organic electroluminescence device | LG DISPLAY CO., LTD. (KR) | 2014-02-11 | — | — | US | disclosed |
| US-8647753-B2 | Organic electroluminescence device | LG DISPLAY CO., LTD. (KR) | 2014-02-11 | — | — | US | disclosed |
| US-8137823-B2 | Anthracene derivatives, process for preparation thereof, and organic electronic light emitting device using the same | LG CHEM, LTD. (KR) | 2012-03-20 | — | — | US | disclosed |
| US-20090079334-A1 | Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same | LG CHEM, LTD. (KR) | 2009-03-26 | — | — | US | disclosed |
| US-20070087222-A1 | Organic electroluminescence device | LG DISPLAY CO., LTD. (KR) | 2007-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090079334-A1 | Novel Anthracene Derivatives, Process for Preparation Thereof, and Organic Electronic Light Emitting Device Using the Same | XPOT, ALAD, APRT | CYP1A2 61/4885SMN1; SMN2 2381/4885ALDH1A1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.